TRIP9 Chemische Eigenschaften,Einsatz,Produktion Methoden

Allgemeine Beschreibung

NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008, or NFKBIB), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664 or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T; R is an A or G purine; and Y is a C or T pyrimidine).[supplied by OMIM

TRIP9 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

TRIP9 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
Shanghai Universal Biotech Co.,Ltd	13774214275	zhouzz@univ-bio.com	China	25004	58
Merck KGaA	21-20338288	ordercn@merckgroup.com	China	6394	58

---

• ANTI-NFKBIB antibody produced in mouse
• Anti-IκB-β, N-Terminal antibody produced in rabbit
• TRIP9
• IKBB
• NFKBIB
• I-κ-B-β
• IκBβ
• NF-κ-BIB
• Major histocompatibility complex enhancer-binding protein MAD3
• NF-κB inhibitor ω
• IKBE
• NF-κ-BIE